Comparison · NCT00252720-dd0274c3
Candesartan vs Placebo: Number of Participants With a Regression of Diabetic Retinopathy.
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Candesartan vs Placebo: Number of Participants With a Regression of Diabetic Retinopathy. Trial comparisons, record NCT00252720-dd0274c3. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00252720-dd0274c3
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.147 | 0.126 | 0.171 | wilson | |
| Risk in group 2 | 0.146 | 0.125 | 0.17 | wilson | |
| Risk difference, group 1 minus group 2 | 0.00151 | -0.0303 | 0.0333 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.01 | 0.813 | 1.25 | log | |
| Odds ratio, group 1 over group 2 | 1.01 | 0.785 | 1.3 | log | |
| Number needed to treat, for one more participant with the outcome on Candesartan than on Placebo | 662 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Candesartan | Candesartan cilexetil 32 mg once daily | 140 | 951 | OG000 |
| Group 2 | Placebo | Placebo Comparator | 139 | 954 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With a Regression of Diabetic Retinopathy.
- Description
Regression of diabetic retinopathy was defined as at least a 3 step improvement or a persistent 2-step improvement (confirmed in 2 consecutive photography sets) in the Early Treatment of Diabetic Retinopathy Study (ETDRS) severity scale. 3 steps were defined as either a 1-step change in one eye and a 2-step change in the other eye or as a 3-step change in one eye only. EDRTS is a scale with 11 steps (1-11).
- Time frame
- From baseline to the end of the study, i.e., 5 years
- Population
- The population was the Intention To Treat population which includes all randomized patients with any post-randomization data.
Source ClinicalTrials.gov
Trial
- Title
- DIabetic Retinopathy Candesartan Trials.
- NCT number
- NCT00252720
- Phases
- PHASE3
- Conditions
- Type 1 Diabetes
- Interventions
- candesartan
- Lead sponsor
- AstraZeneca
- Results first posted
- 2014-06-03
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00252720?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00252720-dd0274c3